Skip to main content
. 2023 May 3;13:1105117. doi: 10.3389/fonc.2023.1105117

Figure 5.

Figure 5

The effect of combined CPT1 inhibitor and fulvestrant treatment on primary and endocrine resistant ER+ breast tumor cell growth. (A–F) Cell survival analysis of the indicated T47D or MCF7 cell lines under the indicated treatments for 4 days. **, and *** denote P-value of < 0.05, 0.01, and 0.005, respectively. NS denotes not significant.